A multicenter, single-arm, clinical trial of adrenomedullin for cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)

Ihara Masafumi0 个研究点目标入组 60 人开始时间: 2021年11月9日最近更新: 2023年10月17日

试验速览

阶段: 2 期
状态: 进行中（未招募）
发起方
入组人数: 60

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: >= 20age old 至 < 90age old（—）
性别: All

入选标准

•1) Patients who have given written informed consent from the patient or the sponsor to participate in the clinical trial
•2) Patients aged between 20 and 90 at the time of obtaining consent
•3) Patients diagnosed as CADASIL after confirming NOTCH3 gene mutation by genetic testing
•4) Patients with Mini-mental state examination-J score of 10-27 or Trail maiking test score (age ajustment) of average + 1.5 SD (standard deviation) or higher

排除标准

•1) Patients who cannot perform cognitive function tests (deafness, blindness, etc., MMSE-J less than 10 points
•Severe cognitive impairment, etc.)
•2) Patients received reatment with prohibited drugs or prohibited therapy within the past 12 weeks from the time of registration
•3) Patients who started to take concomitant restriction drugs or changed dosage of concomitant restriction drugs within the past 4 weeks from the time of registration
•4) Patients whose Mini-mental state examination-J with 4 or more points improvements between the time of registration and 4 weeks or more at the time of screening (If patients who take concomitant restriction drugs)
•5) Patients with active infections requiring antibiotic treatment at registration
•6) Patients with a disability equivalent to modified Rankin Scale 5 at registration
•7) Patients with severe consciousness impairment (Japan Coma Scale 100 or more)
•8) Patients with severe renal impairment (estimated GFR less than 30 mL / min / 1.73m2) at registration
•9) Patients with severe liver damage (transaminase AST (GOT) or ALT (GPT) 100 IU / L or more) at registration
•10) Patients diagnosed as having cerebral infarction or intracranial hemorrhage or transient ischemic attack or cerebral aneurysm with high probability of rupture within the last 12 weeks from the time of registration
•11) Patients with occlusion or severe stenosis of the intracranial main artery or carotid artery at the time of registration
•12) Patients with significant ECG abnormalities (atrioventricular block of 2-3 degrees, extension of QRS interval of 120 ms or more, extension of QTcB of 450 msec or more) at registration, or past histroy of acute coronary syndrome or acute heart failure within the last 12 weeks from the time of registration
•13) Patients with systolic blood pressure less than 100 mmHg at registration
•14) Patients whose pulse rate is less than 45 beats / minute or 120 beats / minute or more at registration
•15) Patients with substance abuse or alcoholism
•16) Patients who cannot perform MRI
•17) Patients with active solid malignant tumors
•18) Patients who do not give consent to contraception from the date of obtaining consent until the end of the safety evaluation period
•19) Pregnant, lactating, and possibly pregnant
•20) Patient who participated in another trial within 24 weeks before registration
•21) Other patients judged by the Investigator or Investigator to be ineligible for this study

研究者

发起方

Ihara Masafumi

相似试验

进行中（未招募）

2 期

A prospective, monocentric clinical trial with adalimumab for topical treatment in chronic woundsL97Ulcer of lower limb, not elsewhere classified

DRKS00000583niversität Leipzig4

进行中（未招募）

1 期

A prospective, monocentric clinical trial with adalimumab for topical treatment of chronic woundsChronic stasis ulcerMedDRA version: 13.1Level: LLTClassification code 10047246Term: Venous stasis ulcerSystem Organ Class: 10040785 - Skin and subcutaneous tissue disorders

EUCTR2009-015749-22-DEniversity of Leipzig18

已完成

1 期

Multiple-dose administration study of adrenomedulli

JPRN-jRCT2080224807niversity of MIyazaki12

进行中（未招募）

1 期

A study of adagrasib for patients with KRASG12C-mutant non-small cell lung cancer (NSCLC), who are elderly or who are unwell because of their lung cancer.

EUCTR2022-002736-31-IEETOP IBCSG Partners Foundation68

进行中（未招募）

1 期

Clinical trial of chemotherapy combination cisplatin + fluorouracil with the novel targeted agent afatinib in patients with inoperable gastric cancerInoperable gastric and gastroesophageal junction cancerMedDRA version: 15.0Level: LLTClassification code 10017760Term: Gastric cancer NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2011-006198-25-GRHellenic Cooperative Oncology Group55